Zurcher Kantonalbank Zurich Cantonalbank Raises Stock Position in Definitive Healthcare Corp. (NASDAQ:DH)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 209.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 16,209 shares of the company’s stock after buying an additional 10,977 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Definitive Healthcare were worth $161,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC purchased a new position in Definitive Healthcare during the 3rd quarter valued at about $116,000. Raymond James & Associates lifted its stake in Definitive Healthcare by 24.2% in the 3rd quarter. Raymond James & Associates now owns 650,327 shares of the company’s stock valued at $5,196,000 after buying an additional 126,613 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Definitive Healthcare by 11.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,090,136 shares of the company’s stock valued at $8,710,000 after buying an additional 113,963 shares during the last quarter. Bordeaux Wealth Advisors LLC purchased a new position in Definitive Healthcare during the third quarter worth $162,000. Finally, M&T Bank Corp raised its holdings in shares of Definitive Healthcare by 142.8% in the third quarter. M&T Bank Corp now owns 80,582 shares of the company’s stock worth $644,000 after acquiring an additional 47,394 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Analysts Set New Price Targets

DH has been the topic of a number of analyst reports. Morgan Stanley lowered Definitive Healthcare from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $11.50 to $9.00 in a research note on Wednesday. Barclays raised their price target on shares of Definitive Healthcare from $10.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Friday, March 1st. Canaccord Genuity Group cut their price objective on shares of Definitive Healthcare from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Wednesday. Finally, Stifel Nicolaus cut their price target on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a report on Wednesday. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.81.

Definitive Healthcare Stock Performance

NASDAQ:DH opened at $5.35 on Thursday. The company has a market cap of $630.18 million, a P/E ratio of -3.01, a P/E/G ratio of 6.12 and a beta of 1.41. The company has a quick ratio of 2.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.20. The firm’s 50 day moving average is $7.70 and its two-hundred day moving average is $8.29. Definitive Healthcare Corp. has a fifty-two week low of $4.38 and a fifty-two week high of $12.45.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The firm had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. Analysts expect that Definitive Healthcare Corp. will post 0.11 EPS for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.